Baxter Healthcare Corporation: Clindamycin Injection Usp In 5% Dextrose, 900 Mg Per
Clindamycin Injection Recall Summary Baxter Healthcare is recalling Clindamycin Injection USP in 5% Dextrose (900 mg per 50 mL) distributed nationwide in the US, Puerto Rico, and Chile due to manufacturing quality control deviations. The affected product is supplied in GALAXY 50 mL single-dose containers under NDC 0338-3814-50. This is classified as a Class II recall, meaning the product could cause adverse health effects.
- Recalling firm
- Baxter Healthcare Corporation
- Product
- Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3814-50.
- Reason
- CGMP Deviations
- Classification
- Class II
- Category
- drug recall
- Country
- United States
- Agency
- U.S. Food and Drug Administration
- Recall date
- 2026-08-06
- Status
- Ongoing
- Areas affected
- AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, ...
- Distribution
- US Nationwide; Puerto Rico; and Chile.
Official recall notice from U.S. Food and Drug Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/0f22119c-5830-4b4a-9bf6-fc898e95d815